Skip to main content

MARSHALL WACE, LLP

Position in SABS — SAB Biotherapeutics, Inc.

CIK 1318757 LONDON, X0

Position in SABS

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$1,776,831
+$892,472 QoQ
Shares Held
463,925
+96.2% QoQ
Ownership
0.510%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Dec 2021
11 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in SABS Over Time

Shares Held

Position Value (USD)

Derivatives in SABS

reported options exposure · as of Sep 30, 2022
CallValue
$0
CallShares
247,576
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,014,740,742 across 267 Biotechnology names.

# Ticker Company Shares Value (USD) Open

All Filings in SABS

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,776,831 463,925
2025-12-31 $884,359 236,460
2024-12-31 $1,742,083 459,168
2024-09-30 $1,239,753 459,168
2024-06-30 $1,423,420 459,168
2024-03-31 $2,084,622 459,168
2023-12-31 $3,154,674 4,585,282
2022-09-30 SABSW 247,576
2022-06-30 SABSW 285,000
2022-03-31 SABSW 285,000
2021-12-31 SABSW 285,000
2021-12-31 $3,889 498